PCI Biotech: Invitation to Q3 2021 result presentation
09 Noviembre 2021 - 5:50AM
PCI Biotech: Invitation to Q3 2021 result presentation
Oslo, Norway, 9 November 2021 - PCI Biotech
(OSE: PCIB) invites to a presentation of the company's Q3 2021
results on Wednesday 17 November 2021 at Oslo Cancer Cluster
Innovation Park.
Time: Wednesday 17 November, 08:30am – 09:30am
CET (local time).Venue: Jónas Einarsson aud. (2nd floor, entrance
2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64,
Oslo.
The presentation will be held in English and if
you wish to attend the presentation in person, please confirm with
an e-mail to post@pcibiotech.com.
The presentation will also be a live webcast and
can be accessed through www.pcibiotech.com. There will be a Q&A
session at the end of the presentation and it will be possible to
post written questions through the webcast console or through a
teleconference facilitated for investors intending to ask questions
verbally during the Q&A session.
PCI Biotech’s Q3 2021 interim report will be
released on 17 November 2021 at 07.00 CET. The interim report and
presentation will be made available on www.newsweb.no and on the
company's webpage, www.pcibiotech.com.
For further information, please contact:Ronny
Skuggedal, CFOEmail: rs@pcibiotech.noMobile: +47 9400 5757
About PCI
Biotech PCI
Biotech is a biopharmaceutical late stage clinical development
company focusing on development and commercialisation of novel
therapies for the treatment of cancer through its innovative
photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms:
fimaChem (enhancement of
chemotherapeutics for localised treatment of cancer),
fimaVacc (T-cell induction
technology for therapeutic vaccination), and
fimaNAc (nucleic acid
therapeutics delivery).
Photochemical internalisation induces triggered
endosomal release that is used to unlock the true potential of a
wide array of therapeutic modalities. The company’s lead programme
fimaChem consists of
a pivotal study in bile duct cancer, an orphan indication with
a high unmet need and without approved products.
fimaVacc applies a unique mode of
action to enhance the essential cytotoxic effect of therapeutic
cancer vaccines, which works in synergy with several other
state-of-the-art vaccination technologies.
fimaNAc utilises the endosomal
release to provide intracellular delivery of nucleic acids, such as
mRNA and RNAi therapeutics, thereby addressing one of the major
bottlenecks facing this emerging and promising field.
For further information, please visit:
www.pcibiotech.com Contact
information: PCI Biotech Holding ASA, Ullernchausséen 64,
N-0379
Oslo
Forward-looking
statements This
announcement may contain forward-looking statements, which as such
are not historical facts, but are based upon various assumptions,
many of which are based, in turn, upon further assumptions. These
assumptions are inherently subject to significant known and unknown
risks, uncertainties and other important factors. Such risks,
uncertainties, contingencies and other important factors could
cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking
statements. PCI Biotech disclaims any obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
This information is subject to the disclosure
requirements pursuant to section 5-12 of the Norwegian Securities
Trading Act.
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Pci Biotech Holding Asa (LSE:0JGL)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024